Real-world clinical and survival outcomes of patients with early relapsed triple-negative breast cancer from the ESME national cohort.

Autor:	Grinda T; Department of Cancer Medicine, Gustave Roussy, 114 Rue Edouard Vaillant, 94800 Villejuif, France; Sorbonne University, Medicine, 21 rue de l'École de médecine, 75006 Paris, France. Electronic address: thomas.grinda@gustaveroussy.fr., Antoine A; Department of Biostatistics, DRCI, Centre Léon Bérard, 28 Promenade Léa et Napoléon Bullukian, 69008 Lyon, France., Jacot W; Department of Medical Oncology, Institut du Cancer de Montpellier, Montpellier University, INSERM U1194, 208 Rue des Apothicaires, 34298 Montpellier, France., Cottu PH; Department of Medical Oncology, Institut Curie, 26 Rue d'Ulm, 75005 Paris & Saint-Cloud, France., de la Motte Rouge T; Department of Medical Oncology, Centre Eugène Marquis, Avenue de la Bataille Flandres-Dunkerque, 35000 Rennes, France., Frenel JS; Department of Medical Oncology, Institut de Cancérologie de l'Ouest Pays de Loire, 15 rue André Boquel, 49055 Angers, France., Mailliez A; Medical Oncology Department, Centre Oscar Lambret, 3 Rue Frédéric Combemale, 59000 Lille, France., Dalenc F; Department of Medical Oncology, Institut Claudius Regaud - IUCT Oncopole, 1 Avenue Irène-Joliot-Curie, 31059 Toulouse, France., Goncalves A; Department of Medical Oncology, Institut Paoli-Calmettes, 232 Boulevard de Sainte-Marguerite, 13009 Marseille, France., Clatot F; Department of Medical Oncology, Centre Henri Becquerel, Rue d'Amiens, 76000 Rouen, France., Mouret Reynier MA; Department of Medical Oncology, Centre Jean Perrin, 58 Rue Montalembert, 63011 Clermont Ferrand, France., Levy C; Department of Medical Oncology, Centre François Baclesse, 3 Avenue du Général Harris, 14000 Caen, France., Ferrero JM; Department of Medical Oncology, Centre Antoine Lacassagne, 06000 Nice, France., Desmoulins I; Department of Medical Oncology, Institut de Cancérologie de Bourgogne, 21079 Dijon, France., Uwer L; Medical Oncology Department, Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, 6 Avenue de Bourgogne, 54519 Vandœuvre-lès-Nancy, France., Petit T; Department of Medical Oncology, Centre Paul Strauss, 3 Rue de la Porte de l'Hôpital, 67000 Strasbourg, France., Jouannaud C; Department of Medical Oncology, Institut de Cancérologie Jean-Godinot, 1 Rue du Général Koenig, 51100 Reims, France., Arnedos M; Department of Medical Oncology, Institut Bergonié, 229 Cours de l'Argonne, 33000 Bordeaux, France., Chevrot M; Department of Research and Development, R&D Unicancer, 101 Rue de Tolbiac, 75654 Paris, France., Courtinard C; Department of Research and Development, R&D Unicancer, 101 Rue de Tolbiac, 75654 Paris, France; University of Bordeaux, Inserm, Bordeaux Population Health Research Center, Epicene Team, UMR 1219, 33000 Bordeaux, France., Tredan O; Department of Medical Oncology, Centre Léon Bérard, 28 Prom. Léa et Napoléon Bullukian, 69008 Lyon, France., Brain E; Department of Medical Oncology, Institut Curie, 26 Rue d'Ulm, 75005 Paris & Saint-Cloud, France., Pérol D; Department of Biostatistics, DRCI, Centre Léon Bérard, 28 Promenade Léa et Napoléon Bullukian, 69008 Lyon, France., Pistilli B; Department of Cancer Medicine, Gustave Roussy, 114 Rue Edouard Vaillant, 94800 Villejuif, France., Delaloge S; Department of Cancer Medicine, Gustave Roussy, 114 Rue Edouard Vaillant, 94800 Villejuif, France.
Jazyk:	angličtina
Zdroj:	European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2023 Aug; Vol. 189, pp. 112935. Date of Electronic Publication: 2023 Jun 07.
DOI:	10.1016/j.ejca.2023.05.023
Abstrakt:	Background: Early metastatic relapse of triple-negative breast cancer (mTNBC) after anthracyclins and/or taxanes based (A/T) primary treatment represents a highly aggressive cancer situation requiring urgent characterisation and handling. Epidemio-Strategy-Medico-Economical-Metastatic Breast Cancer (ESME-MBC) database, a multicenter, national, observational cohort (NCT03275311) provides recent data on this entity. Methods: All ESME patients diagnosed between 2008 and 2020 with mTNBC occurring as a relapse after a systemic neoadjuvant/adjuvant taxane and/or anthracycline-based chemotherapy were included. Early relapses were defined by a metastatic diagnosis up to 12 months of the end of neo/adjuvant A/T chemotherapy. We assessed overall survival (OS) and progression-free-survival under first-line treatment (PFS1) by early versus late relapse (≥12 months). Results: Patients with early relapse (N = 881, 46%) were younger and had a larger tumour burden at primary diagnosis than those with late relapses (N = 1045). Early relapse rates appeared stable over time. Median OS was 10.1 months (95% CI 9.3-10.9) in patients with early relapse versus 17.1 months (95% CI 15.7-18.2) in those with late relapse (adjusted hazard-ratio (aHR): 1.92 (95% CI 1.73-2.13); p < 0.001). The median PFS1 was respectively 3.1 months (95% CI 2.9-3.4) and 5.3 months (95% CI 5.1-5.8); (aHR: 1.66; [95% CI 1.50-1.83]; p < 0.001). Among early relapsed patients, a higher number of metastatic sites, visceral disease but not treatment types, were independently associated with a poorer OS. Conclusion: These real-world data provide strong evidence on the dismal prognosis, higher treatment resistance and major unmet medical need associated with early relapsed mTNBC. Database registration: clinicaltrials.gov Identifier NCT032753. Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Dr. Delaloge discloses: Financial interests, all to my institution (advisory boards, speaker activities): AstraZeneca, MSD, Rappta, Besins, Gilead, Elsan. Research and clinical research funding, all to my institution: Sanofi, Pfizer, Novartis, AstraZeneca, Roche Genentech, Lilly, Puma, Orion, Amgen, Servier, MSD, BMS, Pierre Fabre, Seagen, Exact Sciences, Rappta, Taiho, European Commission, French government, Fondation ARC. Recipient, Horizon 2020 grant MyPeBS. Non-financial interests, personal: Pfizer, Novartis, AstraZeneca, Seagen. Dr. Frenel reports consulting fees from Pfizer, Lilly, Novartis, Astra Zeneca, Clovis Oncology, GSK, Gilead, Daiichi Sankyo, Seagen; honoraria from Lilly, Novartis, Astra Zeneca, Gilead, Daiichi Sankyo, Seagen; support for attending meetings and/or travel from Pfizer, Lilly, Novartis, Astra Zeneca, Clovis Oncology, GSK, Gilead, Daiichi Sankyo, Seagen. Dr. Jacot reports Grants or contracts from Astra Zeneca and Daiichi Sankyo; Payment or honoraria for lectures from Astra Zeneca, Eisai, BMS, Lilly France, Daiichi Sankyo, MSD, Novartis, Pfizer, Roche, Seagen; Participation on a Data Safety Monitoring Board or Advisory Board from Astra ZenecaEisai, BMS, Lilly France, Daiichi Sankyo, MSD, Novartis, Pfizer, Roche, Seagen. Dr. Pérol reports grants or contracts from Roche and ESME, payment or honoraria for lectures from Astrazeneca, Bayer, Boehringher-Ingelheim, Bristol Myers Squibb, Daiichi-Sankyo, Eli-Lilly, Ipsen, Roche, Novartis, Merck Sharp And Dohme, Takeda, Janssen, Pfizer. Dr. Arnedos reports grants or contracts from Roche and Astrazeneca; Consulting fees from Astra Zeneca, Eli-Lilly, Pfizer; Payment or honoraria for lectures from Gilead and Novartis; Support for attending meetings and/or travel from Astra Zeneca, Daiichi-Sankyo, Eli-Lilly; Participation on a Data Safety Monitoring Board or Advisory Board from Novartis, Astra Zeneca. A Antoine reports a grant from the National French Research and Technology Association (ANRT) and Roche (France) via CIFRE doctoral fellowship no. 2020/1054, outside the submitted work. All remaining authors have nothing to disclose. (Copyright © 2023 Elsevier Ltd. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu Full Text from ScienceDirect